Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost

Aug 12 2016

• By Mandy Jackson

DNA

Related Content

Advaxis, Merck to combine immunotherapies for prostate cancer

Aug 26 2014

Merck Bets Moderna's Cancer Vaccines Can Prime Patients For Immunotherapy

Jun 29 2016

Neon Lights Up First PD-1 Combo Study

Dec 16 2015

Amgen's Imlygic 1st FDA-Approved Oncolytic Virus Therapy

Oct 28 2015

Advaxis Sinks On Delayed Disclosure Of Clinical Hold

Oct 07 2015

FINANCE ROUNDUP: VC Investment Not Hurt Yet By Biotech Stock Slump

Oct 07 2015

Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up

Aug 08 2016

Moderna raises $450m; most ever for private biotech

Jan 06 2015

Advaxis Immunotherapy Boosts 12-Month Survival In Cervical Cancer

Sep 18 2015

Dendreon, Geron jobs cut after Valeant, Janssen deals

Mar 05 2015

Gritstone Raises $102m To Climb Cancer Vaccine Mountain

Oct 21 2015

Cancer Vaccines 2.0

Nov 18 2015

Advaxis to fund combination trial with AstraZeneca's MEDI4736

Jul 22 2014

Related Companies

Advaxis, Inc.

Amgen, Inc.

AstraZeneca PLC

Gritstone bio, Inc.

Neon Therapeutics, Inc.

Bristol Myers Squibb Company

Moderna, Inc.

Merck & Co., Inc.

Dendreon Corporation

Bausch Health Companies Inc.

Additional Topics

Personalized Medicine Manufacturing Commercial Deals Research & Development Innovation Cancer BioPharmaceutical

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window